Hydrolysis of Human High-Molecular-Mass Kininogen by Human Plasma Kallikrein. Proposal of a New Model Concept for the Course of Reaction in Presence and Absence of C1-Inhibitor
- 1 January 1987
- journal article
- research article
- Published by Walter de Gruyter GmbH in Biological Chemistry Hoppe-Seyler
- Vol. 368 (2) , 1203-1214
- https://doi.org/10.1515/bchm3.1987.368.2.1203
Abstract
Hydrolysis of high-molecular-mass kininogen was studied by following the changes in the amounts of substrate, intermediates and products as a function of time using quantitative polyacrylamide-gel electrophoresis (silver staining). The experimental data was analysed on the basis of the concept that the overall reaction is composed of three hydrolysis reactions, two positional-change processes of intermediates at the active site, and two product-substrate exchange processes. It is proposed C1--inhibitor to form two types of complexes with kallikrein, one with non-covalent and one with covalent bonds. With an adequately chosen set of reaction-partner concentrations and four different kinds of experimental conditions with respect to kininogen and inhibitor addition to kallikrein, the following results were obtained: 1) Non-covalently bound inhibitor has no effect on the first and the second hydrolysis reaction, but efficiently interferes with the third hydrolysis reaction; 2) Nicked kininogen (first intermediate; one of the two bradykinin bonds split) for the second bond to be hydrolysed undergoes a positional change during which it remains strongly bound to the enzyme, never exchanges with kininogen, and is not displaced by non-covalently bound inhibitor; 3) Intermediate kinin-free kininogen (second intermediate; both bradykinin bonds split and bradykinin released) prior to turning over into stable kinin-free kininogen (final product; histidine-rich fragment split off and released) undergoes a positional change involving dissociation and reassociation so that non-covalently bound inhibitor finds access to the active site; 4) Intermediate kinin-free kininogen to sustain multiple turnovers exchanges with kininogen via a stable complex of such structure that during this process non-covalently bound inhibitor cannot or can only slightly interfere; 5) Stable kinin-free kininogen to sustain multiple turnovers exchanges with intermediate kinin-free kininogen via free enzyme with the effect that non-covalently bound inhibitor efficiently interferes; 6) As hydrolysis proceeds more and more inhibitor becomes covalently bound, gradually leading to complete inactivation of the enzyme.This publication has 26 references indexed in Scilit:
- Completion of the primary structure of human high-molecular-mass kininogen. The amino acid sequence of the entire heavy chain and evidence for its evolution by gene triplicationEuropean Journal of Biochemistry, 1986
- Studies on Human High Molecular Weight (HMW) Kininogen. II. Structural Change of HMW Kininogen by the Action of Human Plasma Kallikrein1The Journal of Biochemistry, 1981
- Surface activation of blood coagulation, fibrinolysis and kinin formationNature, 1980
- Studies of binding of prekallikrein and Factor XI to high molecular weight kininogen and its light chain.Proceedings of the National Academy of Sciences, 1979
- Studies on Human KininogensThe Journal of Biochemistry, 1979
- Identification of prekallikrein and high-molecular-weight kininogen as a complex in human plasma.Proceedings of the National Academy of Sciences, 1976
- Mechanisms for the involvement of high molecular weight kininogen in surface-dependent reactions of Hageman factor.Proceedings of the National Academy of Sciences, 1976
- A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye BindingAnalytical Biochemistry, 1976
- Human Serum Inhibitor of C′1 Esterase: Identity with NeuraminoglycoproteinScience, 1969